PRP for ovarian rejuvenation

What the procedure involves

PRP therapy begins with a blood draw, typically 10–20 ml. The blood is centrifuged to separate and concentrate platelets and growth factors. The resulting PRP solution is then injected into the ovarian stroma, either via transvaginal ultrasound-guided injection or during laparoscopy, depending on the clinic's protocol. The entire process is usually completed as an outpatient procedure.

There is no universal protocol. The number of injections, the volume of PRP used, the centrifugation method, and the timing relative to stimulation cycles all vary between providers. Patients should ask their clinic exactly which protocol is being used and whether it aligns with any published research.

Who this treatment targets

PRP for ovarian rejuvenation is most commonly offered to patients who have been diagnosed with diminished ovarian reserve (DOR), premature ovarian insufficiency (POI), or poor ovarian response in prior IVF cycles. It is not a standard first-line treatment and is generally considered when other options have not produced adequate results.

Age, baseline AMH levels, antral follicle count, and the underlying cause of reduced reserve all affect whether a patient might be considered a candidate. Not every clinic applies the same selection criteria, so eligibility assessments will differ.

Evidence and limitations

PRP for ovarian rejuvenation is not approved or endorsed as a standard treatment by major reproductive medicine organizations. The available clinical data consists primarily of small, uncontrolled studies and case series. Some studies report improvements in AMH levels or follicle development in a subset of patients; others show no measurable benefit. No large randomized controlled trials have been completed as of publication.

Patients should be aware that a rise in AMH or the development of additional follicles does not always translate into a successful pregnancy. The procedure carries procedural risks including infection, bleeding, and ovarian damage, which vary by technique and provider experience.

Questions to ask your doctor

Before proceeding, ask your clinic the following:

1. What is the specific PRP protocol used, and how many injections are planned?
2. Is there published outcome data from your clinic or a comparable patient cohort?
3. What response rate do you see, and how is "response" defined in your practice?
4. How long after the procedure before stimulation is attempted?
5. What are the risks specific to your technique?

If there is no measurable response, what are the next recommended steps?Where to access PRP for ovarian rejuvenation: a country comparison

PRP (platelet-rich plasma) ovarian rejuvenation is an emerging procedure with a limited but growing evidence base. Because it sits outside standard fertility treatment protocols in most countries, availability and clinical experience vary considerably depending on where you seek care.

In Cyprus, PRP ovarian rejuvenation is offered at several fertility centers alongside conventional IVF protocols. It is typically positioned as an adjunct for patients with diminished ovarian reserve or poor response to stimulation. Clinicians in Cyprus have experience combining PRP with IVF cycles for international patients seeking treatment in the same visit.

Thailand has fertility centers — primarily in Bangkok — that offer intraovarian PRP as part of expanded fertility treatment packages. As a procedure without a standard regulatory classification in Thailand, availability depends on the individual clinic's protocols. Any embryos created following PRP treatment must be used within Thailand; frozen embryo export is not permitted.

In Mexico, PRP ovarian rejuvenation is available at private fertility clinics in major cities. Given Mexico's relatively flexible regulatory environment for experimental and adjunct procedures, it is one of the more accessible countries for patients who have not been able to access this treatment elsewhere. Clinics in Cancun and Mexico City offer it as a standalone procedure or as part of an IVF cycle.

Denmark's fertility treatment system is tightly regulated, and PRP ovarian rejuvenation is not a standard offering at most Danish clinics. Patients in Denmark seeking this procedure may need to look abroad, as the evidence threshold required for routine clinical use has not been widely met under Danish medical standards.

In Malaysia, PRP-related fertility treatments are available at a small number of private reproductive medicine centers. Given the early-stage nature of the evidence, not all clinics offer it, and access for patients requiring donor egg IVF in the same cycle remains subject to the existing eligibility restrictions for third-party reproduction in Malaysia.

1. PRP for ovarian rejuvenation is not a guaranteed path to improved egg quality or pregnancy outcomes. Ask any clinic offering it what their specific protocol involves, how they measure response, and what outcomes data they have from their own patient cohort.